Lebrikizumab
- Generic Name
- Lebrikizumab
- Brand Names
- Ebglyss
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 953400-68-5
- Unique Ingredient Identifier
- U9JLP7V031
- Background
Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 430
- Registration Number
- NCT06280716
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan-si, KyÇ’nggi-do, Korea, Republic of
🇰🇷National Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT06243198
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT05735483
- Locations
- 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇨🇦DermEdge Research, Mississauga, Ontario, Canada
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT05559359
- Locations
- 🇺🇸
Great Lakes Research Group, Inc., Bay City, Michigan, United States
🇯🇵Asahikawa Medical College Hospital, Asahikawa, Hokkaido, Japan
🇺🇸Antelope Valley Clinical Trials, Lancaster, California, United States
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT05372419
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Wallace Medical Group, Inc., Los Angeles, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT05369403
- Locations
- 🇺🇸
Direct Helpers Research Center, Hialeah, Florida, United States
🇺🇸Skin Care Physicians of Georgia, Macon, Georgia, United States
🇺🇸Miami Dermatology and Laser Research, Miami, Florida, United States
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
- Conditions
- Interventions
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 331
- Registration Number
- NCT05149313
- Locations
- 🇫🇷
Alm Site 12, Reims, France
🇳🇱Alm Site 35, Utrecht, Netherlands
🇫🇷Alm Site 19, Lille, France
A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 242
- Registration Number
- NCT04840901
- Locations
- 🇺🇸
QPS, Springfield, Missouri, United States
🇺🇸LabCorp CRU, Inc., Madison, Wisconsin, United States
🇺🇸Covance Dallas, Dallas, Texas, United States
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 286
- Registration Number
- NCT04760314
- Locations
- 🇯🇵
Hiroshima University Hospital, Hiroshima-shi, Hiroshima-ken, Japan
🇯🇵KAJI Dermatology Clinic, Nonoichi-shi, Ishikawa, Japan
🇯🇵Kosugi Dermatology Clinic, Kawasaki, Kanagawa, Japan
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 254
- Registration Number
- NCT04626297
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Modern Research Associates, Dallas, Texas, United States
🇺🇸Premier Clinical Research, Spokane, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.